Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

Dejgaard, Thomas Fremming, Frandsen, Christian Seerup, Hansen, Tanja Stenbæk, Almdal, Thomas, Urhammer, Søren, Pedersen-Bjergaard, Ulrik, Jensen, Tonny, Jensen, Andreas Kryger, Holst, Jens Juul, Tarnow, Lise, Knop, Filip Krag, Madsbad, Sten, Andersen, Henrik Ullits·2016·The Lancet Diabetes & Endocrinology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(15)00436-2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 18

  1. 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 · DOI · Paper page
  2. 2014, Standards of medical care in diabetes—2014, Diabetes Care, 37, S14
  3. Holst, 2013, Incretin hormones and the satiation signal, Int J Obes (Lond), 37, 1161, 10.1038/ijo.2012.208 · DOI · Paper page
  4. Kielgast, 2011, Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function, Diabetes, 60, 1599, 10.2337/db10-1790 · DOI · Paper page
  5. Kjems, 2003, The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects, Diabetes, 52, 380, 10.2337/diabetes.52.2.380 · DOI · Paper page
  6. Eng, 2014, Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis, Lancet, 384, 2228, 10.1016/S0140-6736(14)61335-0 · DOI · Paper page
  7. Hari Kumar, 2013, Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study, Diabetes Res Clin Pract, 100, e55, 10.1016/j.diabres.2013.01.020 · DOI
  8. Harrison, 2013, Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs, J Investig Med, 61, 40, 10.2310/JIM.0b013e318279b7d6 · DOI
  9. Kielgast, 2011, Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function, Diabetes Care, 34, 1463, 10.2337/dc11-0096 · DOI · Paper page
  10. Kuhadiya, 2013, Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus, Endocr Pract, 19, 963, 10.4158/EP13065.OR · DOI
  11. Traina, 2014, Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy, Can J Diabetes, 38, 269, 10.1016/j.jcjd.2013.10.006 · DOI
  12. Varanasi, 2011, Liraglutide as additional treatment for type 1 diabetes, Eur J Endocrinol, 165, 77, 10.1530/EJE-11-0330 · DOI
  13. Dejgaard, 2015, Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study, BMJ Open, 5, e007791, 10.1136/bmjopen-2015-007791 · DOI
  14. Sarkar, 2014, Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes, Diabetes Care, 37, 666, 10.2337/dc13-1473 · DOI · Paper page
  15. Vitola, 2009, Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents, Obesity, 17, 1744, 10.1038/oby.2009.171 · DOI
  16. Purnell, 1998, Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial, JAMA, 280, 140, 10.1001/jama.280.2.140 · DOI · Paper page
  17. Davies, 2012, Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 14, 882, 10.1111/j.1463-1326.2012.01595.x · DOI
  18. Bradley, 1999, Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur, Diabetes Care, 22, 530, 10.2337/diacare.22.3.530 · DOI · Paper page

Cited by

See all 179

Metadata

Authors
Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., & Andersen, H. U.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2016-03
Volume
4
Issue
3
Pages
221-232
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2185178624
Cited by
179
References
8
FWCI
12.40
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
Novo Nordisk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(15)00436-2
The paper
Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., & Andersen, H. U. (2016). Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(15)00436-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.